Mounjaro (tirzepatide) is a prescription medication licensed in the UK for type 2 diabetes, with private providers like My London Pharmacy offering access through structured clinical pathways. Private prescription costs for tirzepatide at My London Pharmacy typically range from approximately £199 to £299 per month as of early 2025, depending on dosage strength and service inclusions. This represents a significant ongoing financial commitment compared to NHS provision, where available. Understanding the full cost structure—including consultation fees, monitoring requirements, and dose escalation protocols—is essential for patients considering this once-weekly injectable treatment for diabetes management or weight control.

Mounjaro Cost at My London Pharmacy

Mounjaro (tirzepatide) is a prescription medication licensed in the UK for treating type 2 diabetes. For weight management, tirzepatide is marketed as Zepbound, though availability may vary. My London Pharmacy, like other private pharmacy providers, offers tirzepatide through private prescription services, with costs varying depending on the dosage strength and treatment duration.

At My London Pharmacy, as of early 2025, indicative private prescription costs for tirzepatide typically range from approximately £199 to £299 per month, depending on the specific dose prescribed (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg). These prices generally include the medication itself and may incorporate consultation fees with a prescribing clinician. Patients should confirm current pricing directly with the pharmacy, as costs may change over time.

Patients should be aware that tirzepatide is administered as a once-weekly subcutaneous injection using a pre-filled pen device. The treatment typically follows an individualised dose-escalation schedule, starting at the lowest dose and gradually increasing as tolerated, usually every four weeks, to minimise gastrointestinal side effects and improve tolerability. Dose escalation may be paused or slowed if side effects are problematic.

When considering tirzepatide through My London Pharmacy or any private provider, patients should request a full breakdown of costs, including consultation fees, prescription charges, and ongoing monitoring requirements. Transparency in pricing allows individuals to make informed decisions about their treatment and budget accordingly for what is typically a long-term therapeutic commitment. Patients should also receive guidance on proper pen storage (refrigeration before first use) and safe disposal of used pens in appropriate sharps containers.

NHS vs Private Prescription Costs for Mounjaro

The availability and cost of tirzepatide differ significantly between NHS and private prescription routes in the UK. For type 2 diabetes, Mounjaro (tirzepatide) is available on the NHS in line with NICE Technology Appraisal guidance (TA870). For weight management, NHS availability of tirzepatide is currently limited and subject to specific commissioning arrangements.

For patients who can access tirzepatide through the NHS, the cost would be limited to standard NHS prescription charges—currently £9.90 per item in England, with exemptions available for those who hold a valid medical exemption certificate (including some people with diabetes), those receiving certain benefits, or residents of Scotland, Wales, and Northern Ireland where prescriptions are free. Hospital-supplied medications may follow different charging structures.

NHS eligibility criteria for weight management medications are typically stringent, generally requiring specialist weight management service referral with a BMI threshold (usually ≥35 kg/m² with weight-related complications, or ≥30 kg/m² for people from certain ethnic backgrounds), alongside participation in a structured weight management programme. Specific criteria and stopping rules are defined in the relevant NICE guidance.

Private prescription costs are substantially higher, with indicative prices ranging from £199 to £299 per month at providers like My London Pharmacy as of early 2025. Private access offers treatment without NHS waiting lists, but represents a significant ongoing financial commitment.

Patients should consider that private treatment requires continuous payment for as long as the medication is prescribed—often 12 months or longer for optimal outcomes. In contrast, NHS provision, where available, offers considerable cost savings but with more restrictive eligibility criteria. Individuals should discuss both options with their GP or a specialist to determine the most appropriate and sustainable pathway for their circumstances.

How to Access Mounjaro Through My London Pharmacy

Accessing tirzepatide through My London Pharmacy involves a structured process designed to ensure patient safety and appropriate prescribing. The pathway typically begins with an online consultation or in-person assessment with a qualified prescriber—either a GP, pharmacist prescriber, or specialist clinician registered with the General Medical Council (GMC) or General Pharmaceutical Council (GPhC).

During the initial consultation, the prescriber will conduct a comprehensive medical assessment including:

• Medical history review – evaluating existing health conditions, particularly cardiovascular disease, pancreatitis history, thyroid disorders, and diabetic retinopathy

• Current medications – checking for potential drug interactions and contraindications

• Weight and BMI calculation – confirming eligibility criteria (typically BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities)

• Lifestyle and management goals – discussing diet, physical activity, and realistic expectations

• Safety screening – ensuring tirzepatide is appropriate, noting it is not recommended during pregnancy or breastfeeding

If deemed suitable, the prescriber will issue a private prescription and provide detailed guidance on injection technique, dose escalation schedule, and potential side effects. My London Pharmacy will then dispense the medication, either for collection or via postal delivery, depending on the service model.

Patients should be informed that tirzepatide can reduce the effectiveness of oral contraceptives, particularly after starting treatment or increasing the dose. Additional contraceptive measures may be needed during these periods. Patients taking medications affected by delayed gastric emptying (such as warfarin) may require additional monitoring.

Ongoing monitoring is essential and typically includes follow-up consultations to assess progress, tolerability, and side effects. Patients should stop treatment and seek immediate medical attention if they experience severe abdominal pain (which may indicate pancreatitis), persistent vomiting leading to dehydration, symptoms of gallbladder disease, or signs of severe allergic reaction. Any suspected side effects should be reported through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Factors Affecting Mounjaro Pricing in the UK

Several key factors influence the cost of tirzepatide at My London Pharmacy and other private providers across the UK. Understanding these variables helps patients anticipate expenses and compare services effectively.

Dosage strength is a primary cost determinant. Tirzepatide is available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), with higher-strength formulations generally commanding higher prices. As patients progress through the dose-escalation protocol—typically increasing as tolerated—monthly costs may rise accordingly. Some providers offer tiered pricing structures, whilst others maintain consistent pricing across all doses.

Service package inclusions significantly impact overall costs. Some pharmacies bundle consultation fees, follow-up appointments, and clinical monitoring into the medication price, whilst others charge separately for each component. Patients should clarify whether the quoted price includes:

• Initial prescriber consultation

• Ongoing reviews

• Prescription fees

• Delivery or dispensing charges

• Access to clinical support between appointments

Supply duration also affects pricing. Purchasing multiple pens in advance (e.g., a three-month supply) may attract discounts at some providers, though this requires significant upfront investment and assumes continued suitability for treatment.

Market competition and pharmacy positioning influence pricing strategies. Established providers with comprehensive clinical services may charge premium rates, whilst newer entrants or online-only services might offer more competitive pricing. Geographic location can also play a role, with London-based pharmacies sometimes reflecting higher operational costs.

Regulatory and supply factors impact availability and cost. The manufacturer sets wholesale prices, but individual pharmacies determine retail margins. Patients should compare multiple providers, verify prescriber credentials on the GMC or GPhC registers, and ensure transparent pricing before committing to treatment. As this is a rapidly evolving market, patients should confirm current pricing directly with providers.

Frequently Asked Questions